The New War on Cancer: Four Public Companies Helping Lead a Medical Revolution
Globe Newswire (Thu, 25-Jun 11:39 AM ET)
Summit Therapeutics Launches $500 Million Public Offering to Accelerate Ivonescimab Development
Market Chameleon (Wed, 10-Jun 3:05 AM ET)
Summit Therapeutics Announces Proposed Public Offering of Common Stock
Business Wire (Tue, 9-Jun 4:47 PM ET)
Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference
Business Wire (Thu, 4-Jun 4:30 PM ET)
Business Wire (Sun, 31-May 9:06 AM ET)
Business Wire (Sat, 30-May 8:00 AM ET)
A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology
Globe Newswire (Thu, 14-May 9:15 AM ET)
Globe Newswire (Mon, 4-May 9:23 AM ET)
Business Wire (Thu, 30-Apr 4:32 PM ET)
History Shows SMMT could rally into earnings
Market Chameleon (Wed, 18-Feb 6:46 AM ET)
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Summit Therapeutics trades on the NASDAQ stock market under the symbol SMMT.
As of July 2, 2026, SMMT stock price climbed to $15.42 with 6,921,172 million shares trading.
SMMT has a beta of 2.06, meaning it tends to be more sensitive to market movements. SMMT has a correlation of 0.12 to the broad based SPY ETF.
SMMT has a market cap of $11.96 billion. This is considered a Large Cap stock.
Last quarter Summit Therapeutics reported $0 in Revenue and -$.15 earnings per share. This fell short of revenue expectation by $-40,850 and exceeded earnings estimates by $.08.
In the last 3 years, SMMT traded as high as $36.91 and as low as $1.52.
The top ETF exchange traded funds that SMMT belongs to (by Net Assets): XBI, VTI, VB, VXF, VBR.
SMMT has underperformed the market in the last year with a return of -27.3%, while the SPY ETF gained +21.8%. In the last 3 month period, SMMT fell short of the market, returning -18.5%, while SPY returned +14.0%. However, in the most recent 2 weeks SMMT has outperformed the stock market by returning +9.6%, while SPY returned +1.0%.
SMMT support price is $13.80 and resistance is $14.96 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SMMT shares will trade within this expected range on the day.
